@inproceedings{d2fd93fa441c4c41a4b1661a07e121eb,
title = "Low level laser (light) therapy and photobiomodulation: The path forward",
abstract = "Low level laser (light) therapy (LLLT) also known as photobiomodulation (PBM) therapy has been practiced for almost fifty years, and hundreds of positive clinical trials and thousands of laboratory studies have been published. Despite these impressive accomplishments LLLT has still not reached the stage of acceptance by mainstream medicine. The reasons for this were discussed at a recent Optical Society of America (OSA) Incubator meeting in Washington DC in 2014. Uncertainty about mechanisms was highlighted, and this paper will describe the current thinking. To drive LLLT towards mainstream medicine, we need better guidelines with standardized protocols and consistent parameters. Studies should be published in higher impact scientific and medical journals. Companies should avoid false promises and deceptive marketing, and physicians should receive a clearly defined return on investment with insurance reimbursement.",
keywords = "LLLT, low level laser (light) therapy, mechanism of action, mitochondria, new indications, new light sources, photobiomodulation, TRP ion channels",
author = "Hamblin, \{Michael R.\} and \{Pires De Sousa\}, \{Marcelo Victor\} and Arany, \{Praveen R.\} and Carroll, \{James D.\} and Donald Patthoff",
note = "Publisher Copyright: {\textcopyright} 2015 SPIE.; Mechanisms for Low-Light Therapy X ; Conference date: 07-02-2015 Through 08-02-2015",
year = "2015",
doi = "10.1117/12.2084049",
language = "English",
series = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",
publisher = "SPIE",
editor = "Hamblin, \{Michael R.\} and Praveen Arany and Carroll, \{James D.\}",
booktitle = "Mechanisms for Low-Light Therapy X",
address = "United States",
}